Who makes ARQ-151 cream 0.5%?

ARQ-151 cream 0.5% is developed by Arcutis Biotherapeutics, Inc..

What development phase is ARQ-151 cream 0.5% in?

ARQ-151 cream 0.5% is in Phase 1.

Last reviewed 2026-04-23 · How we verify

ARQ-151 cream 0.5%

Arcutis Biotherapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	ARQ-151 cream 0.5%
Sponsor	Arcutis Biotherapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ARQ-151 cream 0.5% CI brief — competitive landscape report
ARQ-151 cream 0.5% updates RSS · CI watch RSS
Arcutis Biotherapeutics, Inc. portfolio CI